Login to Your Account



Galapagos rolls out positive data on filgotinib in Crohn's

By Nuala Moran
Staff Writer

Monday, September 26, 2016

LONDON – Galapagos NV has added to the body of positive phase II data for filgotinib as its partner Gilead Sciences Inc. continues with the task of getting phase III trials of the oral JAK-1 inhibitor up and running in rheumatoid arthritis, ulcerative colitis and Crohn's disease by the end of 2016.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription